iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Increase in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 100,900 shares, a growth of 11.4% from the June 30th total of 90,600 shares. Currently, 1.2% of the company’s stock are sold short. Based on an average daily trading volume, of 148,300 shares, the days-to-cover ratio is presently 0.7 days.

iBio Stock Down 6.2 %

Shares of iBio stock traded down $0.14 on Monday, reaching $2.11. 50,094 shares of the company were exchanged, compared to its average volume of 1,752,439. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. iBio has a 1-year low of $1.02 and a 1-year high of $15.99.

iBio (NYSEAMERICAN:IBIO) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.71) earnings per share for the quarter.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.